- Home
- WBS vs EXEL Comparison
WBS vs EXEL Comparison
Compare WBS & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WBS | EXEL |
|---|---|---|
| Founded | 1935 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6B | 11.1B |
| IPO Year | N/A | 2000 |
Fundamental Metrics
Financial Performance| Metric | WBS | EXEL |
|---|---|---|
| Price | $71.13 | $43.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 21 |
| Target Price | ★ $73.57 | $46.60 |
| AVG Volume (30 Days) | ★ 4.7M | 2.6M |
| Earning Date | 01-23-2026 | 02-10-2026 |
| Dividend Yield | ★ 2.25% | N/A |
| EPS Growth | 35.01 | ★ 57.95 |
| EPS | ★ 5.90 | 2.78 |
| Revenue | ★ $2,689,413,000.00 | $2,320,126,000.00 |
| Revenue This Year | $3.78 | $14.86 |
| Revenue Next Year | $5.95 | $14.93 |
| P/E Ratio | ★ $12.06 | $15.80 |
| Revenue Growth | ★ 13.63 | 6.98 |
| 52 Week Low | $39.43 | $32.38 |
| 52 Week High | $73.87 | $49.62 |
Technical Indicators
Market Signals| Indicator | WBS | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 63.56 | 53.33 |
| Support Level | $71.54 | $40.92 |
| Resistance Level | $73.87 | $44.28 |
| Average True Range (ATR) | 1.72 | 1.51 |
| MACD | 0.24 | 0.05 |
| Stochastic Oscillator | 72.32 | 78.42 |
Price Performance
Historical ComparisonAbout WBS Webster Financial Corporation
Webster Financial Corp is a full-service provider of financial services, offering commercial and consumer banking, mortgages, and investment advisory along with trust and wealth management services in Connecticut, New York, Rhode Island, Massachusetts, and Pennsylvania. The company's segment includes Commercial Banking, HSA Bank, and Consumer Banking. It generates maximum revenue from the Commercial Banking segment.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.